BioNTech buys Biotheus and its Keytruda rival for $950m
BioNTech said that BNT327 has the "potential to replace current checkpoint inhibitor standard of care treatments for solid tumours." It is paying $800 million to acquire all of Biotheus' issued share capital and up to $150 million in potential milestone payments.
BioNTech strikes $950mn deal for Chinese drugmaker Biotheus
BioNTech has acquired Chinese cancer drugmaker Biotheus in a near $1bn deal, as the Covid-19 vaccine maker taps into the country’s health sciences expertise to develop promising immunotherapy drugs. The deal gives the German biotech control of a drug class that has shown potential to outperform Merck’s blockbuster cancer treatment Keytruda,
The FDA’s premarket approval green light spans one pan-cancer ... Finally, the assay can be used with Merck’s Keytruda ...
Biotheus’ antibody drug targets PD-L1 and VEGF, a design that’s high on drugmakers’ radars after the success of Summit ...
Results from the study, which focused on gynecological malignant tumors, were presented at the Society for Immunotherapy of ...
If, as ivonescimab’s victory over Keytruda suggested, PD-(L ... BioNTech is also exploring combinations with ...
While some of the initial excitement around immunotherapies has waned, companies—particularly smaller biotechs—are developing ...
The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health ...
Keytruda (pembrolizumab) is a prescription drug that’s used to treat certain forms of cancer. Keytruda comes as an intravenous (IV) infusion (an injection into your vein given over time).
As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...
The top 20 biopharmaceutical companies demonstrated signs of recovery during the third quarter (Q3) of 2024 as investor ...
Natalie Willacy has so far poured $40,000 of her super into self-funding her own immunotherapy treatment with the ...
BioNTech SE (BNTX) announced Tuesday that it has signed an agreement to acquire Biotheus, a clinical-stage biotechnology company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback